Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Regeneron Pharmaceuticals, Inc.
  6. News
  7. Summary
    REGN   US75886F1075

REGENERON PHARMACEUTICALS, INC.

(REGN)
  Report
Real-time Estimate Cboe BZX  -  05/27 09:37:26 am EDT
682.36 USD   -0.16%
09:17aInovio Pharmaceuticals Says Brain Cancer Combination Therapy Produced Immune Response in Phase 1/2 Trial
MT
05/23SVB Securities Initiates Regeneron Pharmaceuticals at Outperform with $738 Price Target
MT
05/23Fda approves dupixent (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BofA Securities Downgrades Regeneron Pharmaceuticals to Underperform From Neutral

01/05/2022 | 09:21am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about REGENERON PHARMACEUTICALS, INC.
09:17aInovio Pharmaceuticals Says Brain Cancer Combination Therapy Produced Immune Response i..
MT
05/23SVB Securities Initiates Regeneron Pharmaceuticals at Outperform with $738 Price Target
MT
05/23Fda approves dupixent (dupilumab) as first treatment for adults and children aged 12 an..
AQ
05/23Evkeeza (evinacumab) phase 3 trial demonstrates 48% ldl-c reduction in children with ul..
AQ
05/23FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 ..
AQ
05/23SVB Securities Initiates Regeneron Pharmaceuticals at Outperform With $738 Price Target
MT
05/23Regeneron's Phase 3 Trial Data Shows Positive Results for Potential Treatment of Rare H..
MT
05/21Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with U..
PR
05/20Regeneron, Sanofi Receive US FDA Approval of Dupixent for Eosinophilic Esophagitis
MT
05/20Sanofi's Dupixent wins U.S. approval for bigger use
RE
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 11 835 M - -
Net income 2022 4 041 M - -
Net cash 2022 8 670 M - -
P/E ratio 2022 18,5x
Yield 2022 -
Capitalization 73 638 M 73 638 M -
EV / Sales 2022 5,49x
EV / Sales 2023 4,85x
Nbr of Employees 10 492
Free-Float 81,0%
Chart REGENERON PHARMACEUTICALS, INC.
Duration : Period :
Regeneron Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 683,44 $
Average target price 691,67 $
Spread / Average Target 1,20%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Chairman, Co-President & CEO
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl SVP-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS, INC.8.22%73 638
GILEAD SCIENCES, INC.-11.21%80 866
VERTEX PHARMACEUTICALS22.79%68 965
BIONTECH SE-38.65%38 433
WUXI APPTEC CO., LTD.-25.70%37 870
GENMAB A/S-19.73%19 941